Reduction of Circulating Secretory Phospholipase A2Levels by Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody in Patients with Severe Crohn's Disease
- 1 January 1998
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 33 (10) , 1094-1098
- https://doi.org/10.1080/003655298750026813
Abstract
Background: Secretory phopholipase A2 group II (sPLA2-II) has pro-inflammatory effects. The impor\tance of tumor necrosis factor (TNF) for induction of plasma sPLA2-II in humans was studied in two groups of subjects. Subjects: Six healthy volunteers received a single intravenous injection of recombinant human TNF or isotonic saline at random. Ten patients with active Crohn's disease received a single intravenous infusion of an anti-TNF chimeric monoclonal antibody, cA2. Results: TNF infusion in healthy volunteers resulted in an increase of sPLA2Keywords
This publication has 19 references indexed in Scilit:
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Group II Phospholipase A2 in Sera of Febrile Patients with Microbiologically or Clinically Documented InfectionsClinical Infectious Diseases, 1993
- Reperfusion injury after intestinal ischemiaCritical Care Medicine, 1993
- Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancyEuropean Journal of Haematology, 1993
- Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxinInflammation, 1992
- Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal SubjectsNew England Journal of Medicine, 1990
- Serum phospholipase — Regulatory and pathophysiological aspectsJournal of Molecular Medicine, 1989
- Mediators of InflammationAnnual Review of Immunology, 1983
- The Role of Phospholipase A in Acute PancreatitisScandinavian Journal of Gastroenterology, 1980
- Intracellular phospholipases ABiochimica et Biophysica Acta (BBA) - Biomembranes, 1980